Zim Laboratories Share Price

Zim Laboratories Investment Rating

• Master Rating:

• Zim Laboratories has an operating revenue of Rs. 383.93 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 6% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 45% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 11% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 110 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.